Lung Cancer Research Foundation (LCRF) | 2025 Calls (5)
Event details
| Date | 03.03.2025 |
| Category | Call for proposal |
2025 LCRF Leading Edge Research Grant Program
Aim: Despite being the most common cancer killer of both men and women, lung cancer research remains critically underfunded. To help close this gap and improve outcomes, the goal of the LCRF Leading Edge Research Grant Program is to fund innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, early detection, disparities, and social determinants of health research. General areas of interest available here.
Duration: 2 years
Funding: $150,000
Eligibility: Investigators must be affiliated with a non-profit academic or research institution and must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years’ experience since their initial faculty appointment. For full details, eligibility criteria, and application instructions, please refer to the request for proposals.
2025 LCRF Research Grant on Prevention and Early Detection in Lung Cancer
Aim: This funding mechanism is focused on identifying, characterizing, and developing approaches and techniques that will allow early detection and/or risk reduction of lung cancer and gaining insight into pre-neoplastic processes in the lungs. The ultimate goal is to detect lung cancer at the earliest stages and subsequently increase survival and survivorship. The program is designed to support early-stage researchers and faculty within the first 10 years of their faculty appointment. General areas of interest available here.
Duration: 2 years
Funding: $150,000
Eligibility: Investigators must be affiliated with a non-profit academic or research institution and must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years’ experience since their initial faculty appointment. For full details, eligibility criteria, and application instructions, please refer to the request for proposals.
2025 LCRF Research Grant on Overcoming Resistance in Lung Cancer
Aim: This grant mechanism will focus on furthering the understanding of the development, prevention, and therapy of resistance by supporting projects that seek to identify, characterize, treat or prevent resistance to lung cancer therapies. Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across histological subtypes of lung cancer (including lung adenocarcinoma, squamous cell carcinoma and small cell lung cancer) and across the care continuum including newly designed targeted therapies and immunotherapies. These studies will enhance the momentum of improving lung cancer outcomes and have the potential to increase survivorship. General areas of interest available here.
Duration: 2 years
Funding: $150,000
Eligibility: Investigators must be affiliated with a non-profit academic or research institution and must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years’ experience since their initial faculty appointment. For full details, eligibility criteria, and application instructions, please refer to the request for proposals.
2025 LCRF Minority Career Development Award (CDA) in Lung Cancer
Aim: Minority applicants are less likely to receive grants, to have the R phases of K01 or K99 awards activated, need more submissions to obtain funding, and often will not resubmit proposals. As minority applicants must overcome systemic and structural barriers due to race, ethnicity, country of origin, socioeconomic status, and/or language, many leave academia which further exacerbates the lack of diversity in Science, Technology, Engineering and Mathematics (STEM) and medical fields. To provide protected time and mentoring to these trainees, we continue to offer the LCRF Minority Career Development Award (CDA) for Lung Cancer for minority postdoctoral/clinical fellows and assistant professors within 10 years of completing their MD and/or PhD degrees to submit proposals. General areas of interest available here.
Duration: 2 years
Funding: $150,000
Eligibility: Post-doctoral researchers, clinical fellows, or early-career and mid-career investigators within 10 years of receiving their MD and/or PhD. Investigators must be from racial or ethnic groups that are underrepresented in health-related sciences and biomedical research. This includes Blacks or African Americans, Hispanics or Latinos, American Indians or Alaskan Natives, Native Hawaiians and other Pacific Islanders. Individuals from racial or ethnic groups that can demonstrate convincingly that they are underrepresented by the host institution will also be eligible. For complete details, eligibility criteria, and application instructions, please refer to the request for proposals.
2025 LCRF | Bayer Research Award on Innovative Therapeutic Strategies to Treat Lung Cancers Harboring HER2 Mutations and/or Other HER2 Alterations
Aim: The last 10-15 years have seen accelerated clinical trials and FDA approvals of targeted therapies for non-small cell lung carcinoma (NSCLC) in part due to advances in molecular profiling of tumors. Many of these targeted therapies are directed against oncogenic drivers. The HER family of tyrosine kinases include HER1 (epidermal growth factor receptor [EGFR] or ERBB1), HER2 (HER2/neu or ERBB2), HER3, and HER4. This grant mechanism will focus on the science behind HER2 alterations as oncogenic drivers of malignancy and/or the development of novel therapeutic approaches for patients with tumors harboring HER2 mutations and/or other HER2 alterations. General areas of interest available here.
Duration: 2 years
Funding: $500,000
Eligibility: Investigators must be affiliated with a non-profit, academic or research institution. An applicant must have a postdoctoral or clinical research fellow appointment and/or a faculty position and may have any level of research experience. For full details, eligibility criteria, and application instructions, please refer to the request for proposals.
How to Apply:
Applications should be submitted through the online platform ProposalCentral.
All applications will be evaluated using a two-stage review process that includes review of letters of intent and select full proposals. Applicants will be notified of their status on April 18, 2025, and the full proposal submission deadline is June 2, 2025.
Letter of Intent (LoI) Deadline: 03 March 2025 for all Programs
Further information
Aim: Despite being the most common cancer killer of both men and women, lung cancer research remains critically underfunded. To help close this gap and improve outcomes, the goal of the LCRF Leading Edge Research Grant Program is to fund innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, early detection, disparities, and social determinants of health research. General areas of interest available here.
Duration: 2 years
Funding: $150,000
Eligibility: Investigators must be affiliated with a non-profit academic or research institution and must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years’ experience since their initial faculty appointment. For full details, eligibility criteria, and application instructions, please refer to the request for proposals.
2025 LCRF Research Grant on Prevention and Early Detection in Lung Cancer
Aim: This funding mechanism is focused on identifying, characterizing, and developing approaches and techniques that will allow early detection and/or risk reduction of lung cancer and gaining insight into pre-neoplastic processes in the lungs. The ultimate goal is to detect lung cancer at the earliest stages and subsequently increase survival and survivorship. The program is designed to support early-stage researchers and faculty within the first 10 years of their faculty appointment. General areas of interest available here.
Duration: 2 years
Funding: $150,000
Eligibility: Investigators must be affiliated with a non-profit academic or research institution and must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years’ experience since their initial faculty appointment. For full details, eligibility criteria, and application instructions, please refer to the request for proposals.
2025 LCRF Research Grant on Overcoming Resistance in Lung Cancer
Aim: This grant mechanism will focus on furthering the understanding of the development, prevention, and therapy of resistance by supporting projects that seek to identify, characterize, treat or prevent resistance to lung cancer therapies. Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across histological subtypes of lung cancer (including lung adenocarcinoma, squamous cell carcinoma and small cell lung cancer) and across the care continuum including newly designed targeted therapies and immunotherapies. These studies will enhance the momentum of improving lung cancer outcomes and have the potential to increase survivorship. General areas of interest available here.
Duration: 2 years
Funding: $150,000
Eligibility: Investigators must be affiliated with a non-profit academic or research institution and must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years’ experience since their initial faculty appointment. For full details, eligibility criteria, and application instructions, please refer to the request for proposals.
2025 LCRF Minority Career Development Award (CDA) in Lung Cancer
Aim: Minority applicants are less likely to receive grants, to have the R phases of K01 or K99 awards activated, need more submissions to obtain funding, and often will not resubmit proposals. As minority applicants must overcome systemic and structural barriers due to race, ethnicity, country of origin, socioeconomic status, and/or language, many leave academia which further exacerbates the lack of diversity in Science, Technology, Engineering and Mathematics (STEM) and medical fields. To provide protected time and mentoring to these trainees, we continue to offer the LCRF Minority Career Development Award (CDA) for Lung Cancer for minority postdoctoral/clinical fellows and assistant professors within 10 years of completing their MD and/or PhD degrees to submit proposals. General areas of interest available here.
Duration: 2 years
Funding: $150,000
Eligibility: Post-doctoral researchers, clinical fellows, or early-career and mid-career investigators within 10 years of receiving their MD and/or PhD. Investigators must be from racial or ethnic groups that are underrepresented in health-related sciences and biomedical research. This includes Blacks or African Americans, Hispanics or Latinos, American Indians or Alaskan Natives, Native Hawaiians and other Pacific Islanders. Individuals from racial or ethnic groups that can demonstrate convincingly that they are underrepresented by the host institution will also be eligible. For complete details, eligibility criteria, and application instructions, please refer to the request for proposals.
2025 LCRF | Bayer Research Award on Innovative Therapeutic Strategies to Treat Lung Cancers Harboring HER2 Mutations and/or Other HER2 Alterations
Aim: The last 10-15 years have seen accelerated clinical trials and FDA approvals of targeted therapies for non-small cell lung carcinoma (NSCLC) in part due to advances in molecular profiling of tumors. Many of these targeted therapies are directed against oncogenic drivers. The HER family of tyrosine kinases include HER1 (epidermal growth factor receptor [EGFR] or ERBB1), HER2 (HER2/neu or ERBB2), HER3, and HER4. This grant mechanism will focus on the science behind HER2 alterations as oncogenic drivers of malignancy and/or the development of novel therapeutic approaches for patients with tumors harboring HER2 mutations and/or other HER2 alterations. General areas of interest available here.
Duration: 2 years
Funding: $500,000
Eligibility: Investigators must be affiliated with a non-profit, academic or research institution. An applicant must have a postdoctoral or clinical research fellow appointment and/or a faculty position and may have any level of research experience. For full details, eligibility criteria, and application instructions, please refer to the request for proposals.
How to Apply:
Applications should be submitted through the online platform ProposalCentral.
All applications will be evaluated using a two-stage review process that includes review of letters of intent and select full proposals. Applicants will be notified of their status on April 18, 2025, and the full proposal submission deadline is June 2, 2025.
Letter of Intent (LoI) Deadline: 03 March 2025 for all Programs
Further information
- Application portal can be found here
- For any other questions, please contact the Research Office.
Practical information
- General public
- Free
Contact
- research@epfl.ch